Non-Selective Kinase Inhibitors
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/US2014/010778, filed Jan 9, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,815,815 | Non-Selective Kinase Inhibitors In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | ||
| US 10,246,438 | Non-Selective Kinase Inhibitors Pulmokine Inc.; Gilead Sciences, Inc. and Gilead Sciences, Inc. In force · High confidence | Pulmokine Inc.; Gilead Sciences, Inc. and Gilead Sciences, Inc. | In force | High confidence | ||
| US 10,532,994 | Non-Selective Kinase Inhibitors In force · High confidence | Gilead Sciences, Inc. | In force | High confidence |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.